News Releases
All Releases
View Summary Peregrine Announces Date of 2017 Annual Meeting of Stockholders
Nov 13, 2017
PDF 15.3 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Announces Appointment of Patrick Walsh to Board of Directors of Peregrine and Avid Bioservices
Oct 24, 2017
PDF 21.2 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Announces Appointment of Mark R. Bamforth to Board of Directors of Peregrine and Avid Bioservices
Oct 19, 2017
PDF 22.2 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Reports Financial Results for First Quarter of Fiscal Year 2018 and Recent Developments
Sep 11, 2017
PDF 38.6 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Announces Appointment of Roger J. Lias, Ph.D. as President of Avid Bioservices
Sep 11, 2017
PDF 19.4 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Announces First Patient Dosed in Phase II Clinical Trial Evaluating Bavituximab Treatment Combination in Patients with Newly Diagnosed Glioblastoma
Sep 7, 2017
PDF 26.6 KB Add to Briefcase
View Summary Peregrine to Report Financial Results for First Quarter of Fiscal Year 2018 After Market Close on September 11, 2017
Sep 6, 2017
PDF 14.3 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock
Sep 5, 2017
PDF 13.5 KB Add to Briefcase
View Summary Peregrine Announces Measures to Reduce Costs, Facilitate Profitability and Strengthen its Operations
Aug 11, 2017
PDF 18.3 KB Add to Briefcase
View Summary Peregrine Provides Strategic Update
Jul 31, 2017
PDF 22.6 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Reports Financial Results for Quarter and Fiscal Year Ended April 30, 2017 and Recent Developments
Jul 14, 2017
PDF 46.9 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Issues Statement Regarding Ronin Trading and SW Investment Management's Letter to Stockholders
Jul 13, 2017
PDF 13.9 KB Add to Briefcase
View Summary Peregrine to Report Financial Results for Quarter and Fiscal Year Ended April 30, 2017 After Market Close on July 14, 2017
Jul 7, 2017
PDF 14.4 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Announces Reverse Stock Split
Jul 7, 2017
PDF 17.1 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Declares Quarterly Dividend on its Series E Convertible Preferred Stock
Jun 6, 2017
PDF 14.0 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Presents Preliminary Correlative Analysis of PD-L1 Expression from SUNRISE Trial at ASCO 2017
Jun 5, 2017
PDF 69.1 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Highlights Clinical Data Presentation at AACR 2017 Annual Meeting Supporting Potential of Bavituximab to Enhance Anti-tumor Activity of Immunotherapy
Apr 4, 2017
PDF 56.9 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Announces Presentation of Preclinical Study Results Highlighting Potential of PS-Targeting Antibodies to Enhance Anti-Tumor Activity of Adoptive T Cell Transfer Therapy with No Added Off-Target Toxicities
Apr 3, 2017
PDF 20.7 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Announces Five Abstracts Accepted for Presentation at AACR 2017 Annual Meeting
Mar 23, 2017
PDF 57.5 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2017 and Recent Developments
Mar 13, 2017
PDF 79.9 KB Add to Briefcase
Showing 1-20 of 636 Page: 1 2 3 4 5 ... 32  Next 20
Add to Briefcase = add release to Briefcase
Print E-mail